Allergan swaps director position after investors demand change by Eric Sagonowsky Thursday, June 14, 2018 Rebel investors earlier this month called for changes at Allergan, and now the company has appointed a new director.
Sarepta CEO Ingram nabs $57M in 2017 pay by Eric Sagonowsky Monday, May 7, 2018 Sarepta CEO Douglas Ingram may have netted biopharma's biggest 2017 compensation package after six months on the job.
Warner Chilcott marketing conviction could send doctor to prison by Eric Sagonowsky Tuesday, May 1, 2018 Rita Luthra, M.D., was convicted Monday in a Warner marketing scheme—and in more evidence that it's the cover-up that gets you, for lying to investigators.
Endo, Teva agree to $270M Lidoderm pay-for-delay settlement by Eric Sagonowsky Thursday, March 22, 2018 Endo, Teva and a Japanese drugmaker have agreed to fork over more than $270 million to resolve a class-action suit over Lidoderm.
Grocers take on generic drug industry in price-fixing suit by Eric Sagonowsky Wednesday, January 31, 2018 Kroger and other grocery chains are suing Mylan, Teva, Endo and many other companies for an "overarching conspiracy" to artificially inflate prices.
Judge signals early support for Valeant settlement by Eric Sagonowsky Wednesday, January 17, 2018 Valeant and Pershing Square are one step closer to putting years of insider trading allegations in the past.
Valeant, Pershing Square settle insider trading cases for $290M by Eric Sagonowsky Friday, December 29, 2017 Valeant will pay $96.25 million and Pershing Square will pay $193.75 million to settle insider trading allegations.
Bisaro, Amneal poach top Allergan exec for CEO's chair by Eric Sagonowsky Monday, December 18, 2017 Ahead of an expected merger, the combined company of Amneal-plus-Impax has a new CEO.
Insider trading case against Ackman, Valeant approaches trial by Carly Helfand, Eric Sagonowsky Tuesday, December 12, 2017 Valeant and former activist partner Bill Ackman may once again be thwarted in their efforts to get insider trading claims against them tossed.
Concordia price hikes draw U.K. antitrust probe by Tracy Staton Tuesday, November 21, 2017 U.K. antitrust watchdogs are targeting Concordia and its pricing for liothyonine, a thyroid drug that now costs 57 times more than it did in 2006.
